MEDICAL AFFAIRS & LIFECYCLE DEVELOPMENT
We extend development logic into lifecycle evidence, field insight,
medical strategy and post-launch clinical relevance.
THE LIFECYCLE QUESTION
Protect credibility, independence
and evidence-led communication.
Turn medical insight into action,
not passive reporting.
Build the post-launch studies and
data that keep the asset relevant.
OUR LIFECYCLE PATHWAY
Define the post-approval
opportunity, objectives
and evidence gaps.
Align medical strategy,
stakeholders and
value narrative.
Capture and analyse field insight
from HCPs, KOLs and market signals.
Design and enable lifecycle studies,
RWE and scientific content.
Turn evidence and insight into credible,
non-promotional value.
Maintain momentum through continuous
learning and adaptation.
WHAT WE OFTEN CHANGE FIRST
From promotional messaging to evidence-led, scientifically credible engagement.
From passive reporting to structured insight processes with clear decisions.
From a one-time approval dossier to an active lifecycle evidence plan.
From an undefined medical presence to a clear, high-impact field model.
From ad hoc studies to a prioritised, feasible and strategically aligned lifecycle plan.
NEXT DISCUSSION
Copyright © 2026 Manolo Beelke & Partners. All rights reserved.
